BMS-200

• Description :

  BMS-200 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 80 nM. BMS-200 can induce dimerization of PD-L1[1].

• UNSPSC :

  12352005

• Target :

  PD-1/PD-L1

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/bms-200.html

• Purity :

  98.02

• Solubility :

  DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(O)C[C@H](O)CNCC1=CC(F)=C(OCC2=CC=CC(C3=CC=C(OCCO4)C4=C3)=C2C)C=C1F

• Molecular Formula :

  C27H27F2NO6

• Molecular Weight :

  499.50

• References & Citations :

  [1]Katarzyna Guzik, et al. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. J Med Chem. 2017 Jul 13;60 (13) :5857-5867.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1675203-82-3]